S. Anderson

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

D. Wickerham, N. Wolmark, H. Bear, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22.

D. Wickerham, N. Wolmark, F. Meyers, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer.

D. Zelterman, S. Anderson, Y. Cheng, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience.

J. Bryant, S. Anderson, Roy E. Smith, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.

D. Wickerham, N. Wolmark, S. Anderson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25.

D. Wickerham, N. Wolmark, S. Anderson, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

T. Julian, D. Wickerham, N. Wolmark, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with met

D. Wickerham, A. Glass, H. Bear, 1994, American journal of clinical oncology.